A clinical trial to study the effect of RECEPTOL® , a pure natural nano peptide - antiviral and immunomodulator drug, in patients with HIV / AIDS
- Conditions
- Health Condition 1: null- HIV/AIDS
- Registration Number
- CTRI/2012/08/002931
- Lead Sponsor
- Biomix Network Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
The study will include the patients satisfying the following eligibility criteria:
1) Male and Female subjects between 18 and 60 years of age.
2) Documentation of HIV infection by any approved ELISA test, and the disease contracted heterosexually (no drug abuse) preferably within six months of participation in this trial.
3) With CD4 count greater than 100 cells/cmm
4) With a measurable HIV viral load 5) Subjects willing to give informed consent for their stay in the hospital and / or follow up visits.
The study will include the patients satisfying the following eligibility criteria:
1.Pregnant or nursing women, women of childbearing potential not using an adequate method of
2.birth control.
3. Subjects with kidney failure with Serum Creatinine greater than 1.5 mg/dL.
4. With a history of Hepatic Cirrhosis.
5. Suffering from Congestive Heart Failure (CHF). 6. With current alcohol or substance abuse that could interfere with patient compliance.
7. Organ transplant recipient.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method